Recent Updates
Recently added Catalysts
BBIO

QED And Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability And Activity Of Low-dose Infigratinib In Treating Achondroplasia

Thursday, October 17, 2019 1 min read
Key Takeaway: QED And Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability And Activity Of Low-dose Infigratinib In Treating Achondroplasia

Full Press Release Details

QED And Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability And Activity Of Low-dose Infigratinib In Treating Achondroplasia.
Tags: BBIO Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 17, 2019